Clinical Trial of CRISPR-Edited Cell Therapy Launched for Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

https://www.businesswire.com/news/home/20210712005106/en/Caribou-Biosciences-Announces-Dosing-of-First-Patient-in-Phase-1-Clinical-Trial-Evaluating-CB-010-a-CRISPR-Edited-Allogeneic-Anti-CD19-CAR-T-Cell-Therapy-in-Patients-with-Relapsed-or-Refractory-B-Cell-Non-Hodgkin-Lymphoma
JOIN OUR MAILING LIST

 

 
 
 
 

IPIRA is committed to meeting the needs of people with disabilities in a timely manner by preventing and removing barriers to accessibility. We also adhere to the UC Berkeley policy on nondiscrimination, and protect the privacy of confidential information.